Anavex Life Sciences (AVXL) risk factors, FY2024 10-K

Risks Related to our Company

1. 01We have had a history of losses and no revenue, which raises a risk regarding our ability to continue as a going concern in the future
2. 02We will need additional funding and may be unable to raise additional capital when needed, which would force us to delay, reduce or eliminate our research and development activities

Risks Related to our Business

1. 03Our research and development plans will require substantial additional future funding which could impact our operations and financial condition
2. 04We analyze genomic data from clinical trials to identify biomarkers, which we use in the analysis of our clinical trials
3. 05The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, which could lead to our inability to generate product revenue
4. 06All but one of our clinical trials to date have been conducted outside the United States, and the FDA and other foreign regulatory authorities may not accept data from such trials
5. 07We have received Fast Track designation for one of our compounds and may seek such designation or breakthrough therapy and priority review for other compounds in the future. Fast Track designation or breakthrough therapy designation may not actually lead to a faster FDA review and approval process
6. 08We have received orphan drug designation for several of our compounds, but we may be unable to maintain any benefits associated with orphan drug designation, including market exclusivity
7. 09If we fail to demonstrate efficacy in our non-clinical studies and clinical trials our future business prospects, financial condition and operating results will be materially adversely affected
8. 10If a particular product candidate causes undesirable side effects, then we may be unable to receive regulatory approval of or commercialize such product candidate
9. 11We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy
10. 12If we do not obtain the support of qualified scientific collaborators, our revenue, growth and profitability will likely be limited, which would have a material adverse effect on our business
11. 13We may not be able to develop, market or generate sales of our products to the extent anticipated. Our business may fail and investors could lose all their investment in our Company
12. 14None of our potential drug compounds may reach the commercial market for a number of reasons and our business may fail
13. 15Material modifications in the methods of product candidate manufacturing may result in additional costs or delay
14. 16We have advanced our research and development efforts on the treatment of neurodegenerative and central nervous system, or CNS, disorders, a field that has seen very limited success in product development
15. 17If we fail to compete successfully with respect to partnering, licensing, mergers, acquisitions, joint venture and other collaboration opportunities, we may be limited in our ability to research and develop our potential drug compounds
16. 18The use of any of our products in clinical trials may expose us to liability claims, which may cost us significant amounts of money to defend against or pay out, causing our business to suffer
17. 19In the course of our business, we, or third parties upon whom we rely, may gather, collect, receive, use, transmit, store/retain or dispose of data and confidential information (such as confidential employee information or health-related data), sensitive data, intellectual property and trade secrets
18. 20The occurrence of any event or penalty described above may limit our ability to commercialize our compounds and generate revenue and could require us to expend significant time and resources in response or generate negative publicity
19. 21A variety of risks are associated with operating our business internationally which could materially adversely affect our business
20. 22Our ability to use our net operating loss (“NOL”) carryforwards and certain tax credit carryforwards may be subject to limitation
21. 23We are subject to healthcare laws and regulations which may require substantial compliance efforts and could expose us to criminal sanctions, civil and administrative penalties, contractual damages, reputational harm and diminished profits and future earnings, among other penalties
22. 24We expect current and future legislation affecting the pharmaceutical industry, including drug pricing reform, to impact our business generally, which could adversely affect our business operations
23. 25The coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate product revenue

Risks Related to our Common Stock

1. 26A decline in the price of our common stock could affect our ability to raise further working capital and adversely impact our operations and would severely dilute existing or future investors if we were to raise funds at lower prices
2. 27If we issue additional shares of common stock in the future, it will result in the dilution of our existing stockholders and may cause the share price of our common stock to fall
3. 28Our stock price has been volatile and may be volatile in the future
4. 29Our common stock may become the target of a “short squeeze.”
5. 30Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud

Risks Related to our Intellectual Property

1. 312. Because of the time, money and effort involved in obtaining and enforcing patents, our management may spend less time and resources on developing potential drug compounds than they otherwise would, which could increase our operating expenses and delay product programs
2. 326. If a court decides that an Anavex compound, its method of manufacture or use, infringes on a competitor’s patent, we may have to pay substantial damages for infringement
3. 338. Redesigning our potential drug compounds so that they do not infringe on other patents may not be possible or could require substantial funds and time
4. 34We may also support and collaborate in research conducted by government organizations, hospitals, universities or other educational institutions. These research partners may be unable or unwilling to grant us exclusive rights to technology or products derived from these collaborations
5. 35Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
6. 36If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business
7. 37Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts
8. 38If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business would be harmed
9. 39We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers
10. 40We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful and could harm our business
11. 41We may be subject to claims challenging the inventorship of our patents and other intellectual property
12. 42Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
13. 43We may not be able to protect our intellectual property rights throughout the world
14. 44Changes in patent law could diminish the value of our patents and patent applications in general, thereby impairing our ability to protect our product candidates